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ABSTRACT
Scientific and clinical reports globally demonstrated that the opportunistic mycotic infections are at major risk to the human fitness. In the past few 
decades, the development of resistance in microbes to existing antifungals has emphasized on the search of new antimycotic drugs. As a matter of fact, 
“echinocandins” are new categories of broad-spectrum antifungal enlighten a hope in this direction. Echinocandins are bulky lipopeptides that inhibit 
the production of β-[1,3]-glucan “a major constituent of fungal cell wall” which ultimately leads to the death of fungal pathogens. In vitro as well as 
in vivo published reports have demonstrated that the echinocandins exhibit fungicidal activity against most Candida spp., while fungistatic against 
Aspergillus spp. and exclusively found to be more effective when tested in combination with polyenes/azoles. The present article is expert views on 
the recent and historical literature available on the antifungal therapies with accessing their impact on the human health. Emphasis is given to the 
utility of the echinocandins a potental antifungal agent by discussing recent examples of clinical and laboratory studies including the use of improved 
proteomics approaches to know a bit more about the interaction of human host and fungal pathogens.
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INTRODUCTION
A normal resident flora of the body also includes pathogenic microbes, 
which develop disease only when host immune defense is weak. 
Opportunistic mycoses are the type of fungal infections mostly 
occurring in the host with compromised immune system. Over the 
past few decades, the incidence of invasive fungal infections due to 
opportunistic pathogens has been escalated significantly [1]. This 
upsurge in infections is coupled with extreme morbidity/mortality [2], 
also the individuals undertaking blood/bone marrow transplantation, 
solid organ transplantation, and major surgery are at higher risk of 
such kind of infections [2,3]. Highest frequencies of opportunistic 
fungal infections are due to different species (spp.) of Candida 
(Candidiasis and Candidaemia) and Aspergillus (Aspergillosis). Current 
medical treatments are of limited utility, and their therapeutic use has 
been complicated by Candidaemia and invasive Candidiasis (IC), which 
contribute toward high morbidity and mortality [4]. Candidaemia is 
the fourth major type of microbial bloodstream infection [5], while 
Candida albicans being the major causative spp. for the development 
of IC [6]. Over the past two decades, the prevalence of Candidaemia has 
boosted as per the hospital records, which has shown the incidence 
ranging from 24% to 57%. In a report out of 670 cases of Candidaemia, 
274 (41%) were hospital acquired, among which mortality turned out 
to be 39% [7] Both C. albicans and Candida non-albicans species are 
known to colonize the skin, gastrointestinal tract and reproductive tract 
in humans apart of Candidaemia, Invasive Aspergillosis (IA) which is 
caused by spp. of Aspergillus (Aspergillus fumigatus, Aspergillus flavus, 
Aspergillus terreus, and Aspergillus nidulans), has also been emerged as 
a major life risk in immunocompromised patients [8]. Recently, in an 
18 month surveillance program, among 5.561 patients, only 12 patients 
were reported to be suffering from IA (0.2%). However, mortality was 
found to be 60% [9]. Furthermore, researchers affirmed 7% of IA 
affected cases by a mortality rate of 91%. Remarkably, 70% of these 
cases had been observed with no predisposing factors for opportunistic 
mycotic infections [10].
At present, major drugs used for systemic therapy of opportunistic fungal 
infections have different main targets: The polyenes and azoles affect 
the plasma membrane, whereas the antimetabolite, 5-fluorocytosine 
restricts DNA and RNA synthesis whereas echinocandins acts on the 
cell wall of the pathogens. Flucanozole targets lanosterol 14-alpha-
demethylase and hinder the biosynthesis of ergosterol [11]. Since the 
first polyene was standardized 40 years earlier, the echinocandins 
were approved in January 2001 as a new class of antifungal drug. 
Different types of echinocandins include micafungin (MCF) (Mycamine, 
Astellas) which was accepted in 2005 and anidulafungin (ANF) (VER-
002, V-echinocandin, LY303366, Vicuron Pharmaceuticals) accepted in 
2006; further, these two classes of echinocandin have been approved 
by the federal drug administration [12]. Since 2000, echinocandins 
have been extensively used for the cure and prophylaxis of invasive 
mycoses (IM) [13] and majorly suggested as first-line treatment for 
Candidiasis [14].
Echinocandins reveal effective antifungal activity against major infectious 
fungi, such as Candida spp., Aspergillus spp., and Pneumocystis carinii. 
However, in case of Cryptococcus neoformans, current echinocandins 
lack in vitro activity. Although, semisynthetic echinocandins are on 
more beneficial sides like favorable pharmacokinetics allowing once-
daily administration low toxicity and fast antifungal activity. The 
echinocandins lately accessible for clinical purposes are caspofungin 
(CAS), MCF, and ANF [15]. Results of clinical practices applied in China 
suggest that CAS has been superior to the other two antifungal drugs 
classes: Polyenes and azoles, because of its efficiency in curing fungal 
infections (15% superior to fluconazole); minor adverse effects such 
as hepatic dysfunction, infusion-related reaction and vomiting (25-50% 
lower frequency); rapid resolution of symptoms (almost 3 days faster 
than Amphotericin B [AmpB]); and no antagonism in combination 
therapy [16].
Constant efforts are needed to develop the suboptimal remedial 
results linked with mycotic infections. However, monotherapy is often 
diagnosed with increased risk of toxicity, lesser resistance, or limited 
spectrum of activity. These limitations of monotherapy led to determine 
efficacy of combination therapy for the treatment and management of 
IM [17]. There are various probable benefits to combination antifungal 
therapy, i.e., wide spectrum and effectiveness of drug activity, speedy 
antifungal effect, synergy, limited dose, and chance of antifungal 
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resistance is reduced. Although every antifungal agent has its own 
restrictions, therefore, combination therapy might become more 
efficient for the treatment of IM [18].
In this article, we have emphasized on echinocandins being potential 
source as an antifungal agent, their improved efficacy in combination 
with currently available antifungals including pharmacokinetics 
investigations have been discussed along with available reports on 
genomics and proteomics based studies, for elucidating the mechanism 
of action of these antifungal drugs.
ECHINOCANDINS: THE POTENTIAL SOURCE AS AN ANTIFUNGAL 
AGENT
Recently, only a few antifungals are in use that has significant efficacy 
against fungal infections. These antifungal drugs affect specifically the 
components constituting cell membrane of fungi or its biosynthetic 
pathways. However, more recent class of antifungals in use is 
echinocandins [19], which disrupts cell wall components by non-
competitively inhibiting the synthesis of 1,3-β-glucans. First reported 
echinocandin was CAS, followed by MCF and ANF. CAS is found to be 
most effective against candidal esophagitis and candidemia, along with 
salvage therapy of Aspergillus infections and for empirical therapy 
of febrile neutropenia. Likewise, MCF is used in treating candidal 
esophagitis and cases of hematopoietic stem cell transplants. ANF has 
also been considered an effective drug to cure candidal esophagitis, 
Candidaemia [20].
Echinocandins seems the smart new choice for the cure of IM 
infections because of their reduced toxicity and slight drug-drug 
interactions. They are found to be fungicidal against yeast and 
fungistatic against mold. However, their price may reduce their usage 
during initial therapy in cases with fungemia in medical centers 
or ICU with a high rate of triazole-resistant Candida infections. 
Reportedly, Echinocandins act fungicidal against Candida spp. along 
with triazole-resistant isolates and show fungistatic activities against 
Aspergillus spp. echinocandins also reveal concentration-dependent 
activity against Candida spp. Although echinocandins are fungistatic 
against mold, according to one study, they might prove promising for 
treating opportunistic infections when administered in combination 
with AmpB or wide-spectrum triazoles, such as voriconazole. 
Reviews suggest that in clinical trials, CAS exhibit efficacy in curing 
eosophageal candidiasis, candidemia, and febrile neutropenia. 
However, MCF seems effective in hematopoietic stem cell transplant 
recipients and the treatment of esophageal candidiasis. ANF received 
approved labeling from the Food and Drug Administration in February 
2006 [21].
Since 2000s, echinocandins are extensively recommended for the 
treatment of invasive fungal infections, remarkably, and IC. Although, 
cases of advance candidiasis in hosts, taking echinocandins, have been 
detected; however, the rare incidence of clinical failure is observed 
due to the possession of resistance by a generally susceptible Candida 
spp. isolate [13]. Reportedly, in vitro activity of antifungal drugs was 
tested against 496 isolates of yeasts and molds, during 2010-2012. Fks 
hot spots were sequenced for strains resistant to echinocandins and 
resistance was found infrequent among 8 Candida spp. and was only 
spotted in 3 isolates of Candida glabrata, having mutations in fks1 
(F625S) and fks2 (S663P) [22].
Another study of 163 hosts during 2011-2012, revealed the fact that 
echinocandin failure was rare and molecular investigations of the fks1 
and fks2 hotspots of the C. glabrata, discovered mutations only in 2 
isolates (L628R and S629P in fks1) [23].
Furthermore, a report comprising data from 2008 to 2013 suggested 
that, among 1.380 hosts of C. glabrata, 3.1% were resistant to ANF, 
3.3% were non-responsive to CAS and 3.6% were not affected while 
treated with MCF [24].
Mechanism of resistance
Echinocandin resistance in C. glabrata is associated entirely with 
fks1p and fks2p amino acid substitutions [25]. Echinocandin failure 
accredited to mutations in fks1 is linked with raised chitin levels and 
the lack of a compensatory upsurge in chitin level on echinocandin 
introduction (Table 1) [26].
MONOTHERAPY/COMBINATION THERAPY OF ECHINOCANDINS 
AND THEIR CHEMICALLY MODIFIED DERIVATIVES
Echinocandins in combination with polyenes
Recently, combination antifungal therapy of echinocandins with 
polyenes has been explored in nonclinical studies for boosting the 
effect of the treatment for IA. AmpB aims at ergosterol present in fungal 
cell membrane by binding with it consequently creating pores in the 
membrane and disrupting membrane integrity, resulting in fungal cell 
lysis [27]. However, the echinocandins mainly focus the enzyme 1,3-β-D-
glucan (BG) synthetase, required for the synthesis of 1,3-BG, a vital 
component of fungal cell wall [28]. The specificity of the echinocandins 
against the fungal cell wall also seems promising for least hazardous 
side effects. Hence, combination of a drug, which aims at the cell wall 
and the one, targeting the plasma membrane, might result in additive 
or synergistic antifungal effects. Nonclinical reports suggest that the 
combination of AmpB and the echinocandin does not act antagonistic 
during the treatment of Aspergillus infections [29].
Indeed, enhanced efficiency has been displayed by mice model 
(affected with chronic granulomatous disease and pulmonary IA) when 
administrated with combination of MCF (Mycamine) and AmpB [30] 
and in case of murine systemic aspergillosis, increased efficacy has 
been reported when treated with a combination of CAS plus AmpB or 
intra-lipid AmpB (LAmpB) [31]. Whereas, Clemons and Stevens [29] 
reported that there was no synergistic activity of MCF and AmpB for 
pulmonary IA in immunocompromised DBA/2 mice, although there 
was no antagonism too.
In another case of a Systemic Murine Aspergillosis model [32], the 
researchers observed narrow additive effects of suboptimal doses of 
LAmpB and MCF with appreciably decreased fungal load in the spleens 
when treated with LAmpB before MCF. Although for the disseminated 
and pulmonary murine infections, administering LAmpB along with 
MCF or CAS, was reported to be neither antagonistic or additive nor 
synergistic although improved survival or decrease in fungal load also 
considered. However, Wasan et al. [33] observed additive effects in a 
rat model (infected with A. fumigatus) when it was exposed LAmpB 
(5 mg/kg) plus CAS (3 mg/kg), parallely. In this study, the researchers 
reported that the combination appreciably reduced colony forming unit 
(CFU) (by 98%), while LAmpB or CAS monotherapy reduced 69% and 
80% CFU, respectively, in comparison with untreated controls.
Instead of combination therapy, researchers analyzed the decline of 
fungal load in kidneys during disseminated infection, was appreciably 
improved when LAmpB was administered previous to CAS instead of 
CAS was given first (sequential therapy) [34].
In conclusion, treatment of disseminated or pulmonary infection 
of A. fumigatus in mice, with LAmpB + echinocandin or exposure of 
LAmpB previous to the echinocandins, was equally efficient as LAmpB 
treatment alone, but with prolonged survival and reduced fungal load in 
the target tissues. In contrast, unlike pulmonary infection, in the hosts 
of disseminated infection, survival was prolonged by echinocandin 
monotherapy, and in general, did not considerably decrease the fungal 
load compared to LAmpB. Taken both models into account, there was 
appreciably improved effect when LAmpB was given earlier to the 
echinocandins; these explanations deliver a convincing evidence for 
using LAmpB first if sequential therapy is used for IA [35].
Echinocandins in combination with azoles
A research, including 101 cases (79 proven, 22 probable), across four 
risk groups (patients with hematologic malignancy, stem cell recipients, 
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solid organ transplantation hosts and other), and two periods, 
P1 (1995-2003) and P2, (2004-2011); revealed that amid periods, the 
fraction of patients, diagnosed with hematologic malignancy or solid 
organ transplant recipients, intensity from 47% to 73%, while “other” 
declined from 33% to 11% with probability (p) of 0.036. However, 
between periods, the cumulative prevalence of invasive infections did 
not appreciably escalated in stem cell transplant recipients (p=0.27) or 
solid organ transplant recipients (p=0.30). Notably, more patients were 
given amphotericin-echinocandin combination therapy in P2 (31% vs. 
5%, p=0.01); though, no improvement was observed during 90-days 
survival (54% vs. 59%, p=0.67) [34].
Combination therapy of pediatric IM has hardly been reported. In a 
research, conducted on 19 children (with a median age of 5.3) affected 
with IM, were administered with liposomal LAmpB monotherapy for 
a median duration of 12 days (range 3-69 days). As patients were 
obstinate to LAmpB; therefore, CAS was supplemented in 11 patients. 
In the remaining 6 cases, LAmpB was stopped and a combination of 
CAS and voriconazole were commenced. 12-week survival rate of these 
patients was 75% with no hazardous side effect. Data suggest that 
combination antifungal therapy is safe and effective in children with 
hematological malignancies [36].
In a more recent study involving 10 randomized controlled trials, 
involving 2,837 hosts, echinocandins and triazoles exhibited parallel 
outcomes in terms of promising treatment success rate such that 
the relative risk (RR)found to be 1.02, fungal success rate with RR 
of 0.98, advance infection RR to be 1.09, drug-associated adversity 
with RR 0.94, and all-cause mortality (RR=0.85; 95% cumulative 
prevalence, 0.66-1.10). Moreover, echinocandins were found to be more 
efficient than triazoles in case of patients diagnosed with hematologic 
malignancies or hematopoietic stem cell transplantation recipients 
with RR of 1.08. Echinocandins appreciably reduced the adverse 
effects linked to the withdrawal rate in comparison with triazoles 
(RR=0.47) [37].
In a randomized, double-blind, placebo-controlled, multicenter trial from 
93 international sites, 454 patients with hematologic malignancies or 
hematopoietic stem cell transplantation and proven or probable IA, were 
randomly given voriconazole and ANF. For combination therapy, mortality 
rates observed at 6 weeks, was 19.3% (26 of 135) and for voriconazole 
monotherapy, it was, 27.5% (39 of 142) (p=0.087); concluding that 
as compared to single drug administration, combination therapy of 
voriconazole with ANF exhibited greater survival in patients with IA [38].
In another research, it was found that combination therapy (MCF and 
daily dose of oral 400 mg itraconazole) can be promising alternative for 
treatment of fatal IA of the sinus [39].
A study conducted in Germany from 2006 to 2012 in patients with 
acute alternative lymphoblastoma leukemia and hematopoietic stem 
cell transplantation recepients having IM. Out of 25 patients of acute 
lymphoblastoma leukemia along with 28 cases of suspected IM, 20 
were administered with empirical CAS first line monotherapy (71.4%), 
5 were given second line monotherapy (17.9%) and combination 
therapy in 3 cases (10.7%) concluding that empirical CAS seems to 
be a successful therapeutic alternative in case of IM having acute 
lymphoblastoma leukemia with probable IM [40].
In an observational study conducted in Japanese patients, from 
July 2007 to June 2010, it was observed that among 241 patients, 
86 patients (35.7%), were diagnosed with 143 adverse drug reactions, 
especially hepatobiliary disorders. The clinical success rate was 72.8% 
(131/180 patients), and the prevalence of advance infections was 
merely 4.4% (8/180 patients) concluding that MCF had satisfactory 
efficiency against IM in Japanese episodes undergoing hematopoietic 
stem cell transplantation [41].
Present recommendations acclaim antifungal measures for children 
who are at high risk for IM, though the administration of polyenes 
and triazoles may not be recommended in some episodes due to 
toxicities and drug-drug interactions. Although Azole antimycotic 
drugs are administered clinically in patients with IM, these agents 
have been detected with renal toxicity thus causing vomiting. Thus it 
has led to requirement of new antifungal agents with minimum toxic 
effects, although an investigation for the noval antimycotic metabolites 
remains new area of research [42]. In an analysis, including 21 IM 
affected children with a median age of 9, it was concluded that receiving 
MCF between 3 and 4 mg/kg of body weight, two times every week, 
could be an appropriate, nontoxic and effective substitute for antifungal 
prophylaxis [43].
Recently, Antonio Roseto and coworkers reported that ANF exhibited a 
convincing in vitro activity against both planktonic and biofilms cells. 
This analysis involved nine Candida strain biofilms: Four C. albicans, 
two C. glabrata and three Candida guilliermondii and it was found that 
ANF alone was active against biofilms whereas ANF in combination 
with three non-steroid anti-inflammatory drugs (NSAIDs): Aspirin, 
diclofenac and ibuprofen, proved synergistic in action against Candida 
Table 1: Mechanism of resistance of pathogenic species against diverse antifungal drugs [12]




Binds with ergosterol 
present in plasma 
membrane
Candida lusitaniae, Candida 
lipolytica, Candida guillermondii, 
Trichosporon beigelii, 
Pseudallescheria boydii and 
Scopulariopsis
Decrease in the ergosterol content due to the 
absence of the enzyme, D-isomerase








Binds with lanosterol 
demethylase in plasma 
membrane
Candida neoformans, Candida 
albicans, Candida dubliniensis, 
Candida norvegensis, and Candida 
inconspicua
Alteration or overexpression of the target 
14-α-DM enzyme
Mutation in the ergosterol 
pathway [defectiveα-5,6-desaturase, encoded 
by the gene ERG3]
Amino acid substitutions
Antimetabolite Flucytosine Act as scavenger for 
salvage pathway
Candida spp. Candida neoformans, 
Candida albicans
Mutational decline of cytosine permease or 
deaminase activity






inhibition of cell wall 
protein β-1,3-glucan 
synthase
Candida glabrata Fks1p and fks2p amino acid substitutions
Deletion of genes coding for components 
related with cell wall integrity, such as WSC1, 
PKC1, BCK1, and SLT2
57
Asian J Pharm Clin Res, Vol 10, Issue 8, 2017, 54-59
 Narwal et al. 
spp. biofilms. These findings may suggest new therapeutic stratergies 
of ANF with NSAIDs against Candida biofilm-related IM [44].
Echinocandin in combination with adjunctive agents
Hematopoietic growth factors encourage the proliferation and 
stimulation of phagocytic host cells; out of these, colony-stimulating 
factor (G-CSF), GM-CSF, and M-CSF have been considered as adjunctive 
immunomodulatory agents against fungal pathogens.
G-CSF incites the production and differentiation of myeloid progenitor 
cells to polymorph nuclear leukocytes, such that raising the quantity 
of mature neutrophils. Moreover, In vitro G-CSF boosts the phagocytic 
activity of neutrophils along with respiratory burst against Aspergillus 
spp. [44,45] In neutropenic animal models of IA, G-CSF treatment 
was coupled with improved survival as well as quicker recovery from 
neutropenia [46].
ADVANCE THERAPIES FOR BETTER TREATMENT STRATEGIES AND 
NEED FOR NOVEL DRUG TARGET IDENTIFICATION
As most of the pathogenic spp. of Candida and Aspergillus has 
developed resistance against standard antifungal drugs, there is a need 
to search advance therapies for better treatment of IM. Recently, a novel 
echinocandin-type antifungal metabolite, MIG0310, with a molecular 
formula C(48)H(66)O(18) was isolated and characterized, obtained 
originally from fungal strain, Fusarium MS-R1, has led to the idea of 
developing new antifungal drugs against resistant Candida spp. [47].
Another interesting research showed that an inhibitor of Hos2 
fungal histone deacetylase named as MGCD290 employs a noticeably 
satisfactory impact on the minimum inhibitory concentrations 
(MICs) of fluconazole and the echinocandins, showing synergy when 
administered in combination, converting resistant Candida spp. to 
susceptible, irrespective of fks mutations [48].
In 2015, Wiederhold et al. [49] confirmed in vitro and in vivo 
antifungal activity of arylamidine, T-2307 against C. albicans, 
resistant to echinocandin along with usefulness of the untried 
echinocandin ASP9726 in a guinea pig affected with IA. Guinea pigs 
were subcutaneously injected with investigational echinocandin at 
different concentrations, and plasma concentrations were noted. 
Immunocompromised guinea pigs were infected with A. fumigatus 
and three drugs (ASP9726, voriconazole, CAS) were given for 8 days. 
Measurement of variations in fungal burden showed that ASP9726 
plasma concentrations were raised proportionally with every dose, and 
the drug was well tolerated at every dosage. Every dosage of ASP9726, 
voriconazole, and CAS appreciably reduced the infection. Similarly, 
ASP9726 at 5 mg/kg had considerably improved survival [50].
Current epidemiological investigations have disclosed rise in number of 
C. glabrata revealing reduced echinocandin sensitivities. The significant 
contribution in maintaining integrity of fungal cell wall is done by the 
Slt2 mitogen-activated protein kinase pathway. Some transcription 
factors such as Rlm1 and Swi4-Swi6 cell cycle box binding factor 
(SBF) have been reported downstream of Slt2 such that Slt2 and Rlm1 
display significant response to MCF exposure, though, no such data 
available for SBF in C. glabrata. Hence, researchers produced some 
C. glabrata strains with the lack of SBF (∆swi4 and ∆swi6 strains) or 
overexpressing SBF (SWI4 and SWI6 strains) and estimated their 
susceptibilities against MCF. MCF resistance substantially declined in 
the ∆swi4 strain, whereas it amplified in SWI4 strains concluding that 
although Swi4 is principally responsible for MCF resistance more than 
Swi6 in C. glabrata. Moreover, the overexpression of RLM1 stimulated 
added MCF tolerance in the wild-type strains, but not in the ∆swi4 and 
∆swi6 strains, proposing that Rlm1 and SBF act collectively in response 
to MCF administration [51].
In a study conducted on 257 patients, with probable IC and getting 
ANF administration, were evaluated clinically and microbiologically 
along with measuring their serum (1,3)-BG serially. BG can be used as 
a biomarker for IC. Correlation of initial and final BG levels with overall 
outcome was assessed in each patient and success rate found to be 
85%. Success of treatment was correlated with a reduction in BG levels 
and early BG of <416 pg/ml can predict promising treatment result 
especially for patients with IC receiving predominantly echinocandin 
therapy [52].
In another study, BG surveillance in ICU patients infected with IC getting 
ANF administration showed that ICU patients with proven or probable 
IC have higher BG levels than ICU patients without IM. Preemptive ANF 
was nontoxic and often successfully tolerated with exceptional results. 
BG surveillance may be effectul in diagnosing ICU patients with a 
greater probability of developing IM [53].
LATEST TECHNIQUES FOR MULTIFACTOR ANALYSIS INCLUDING 
PROTEOMIC DATA
Non-ribosomal peptide synthetases (NRPSs) are the main enzymes 
in fungal peptidic association and are accountable for some of the 
best-known, supreme beneficial and record devastating fungal 
metabolites. Most of NRPS encoding genes of any fungal spp. can now 
be identified by genome sequencing and recognizing the catalytic 
domains using bioinformatics. Genomic sequencing and annotation 
has lately categorized the gene clusters accountable for two significant 
classes of NRP fungal derivative drugs, cyclosporine and the 
echinocandins. Genetic mapping of these gene assemblies has been 
done and characterization of their function is still in progress. Genomic 
sequencing of wild type and variants of echinocandin family has made 
it possible to understand the fundamental architecture of echinocandin 
NRPS pathways [54].
In a study comparing the echinocandins activity against 7 C. albicans, 
5 C. dubliniensis, and 2 C. africana spp. by time-kill analysis, MIC values 
were found to be similar for the 3 spp. as echinocandins displayed 
weak killing activity and no mortality against C. africana. This study 
suggests time - kill analysis can be taken as a promising diagnostic tool 
for identification of new pathogenic spp. especially when echinocandin 
therapy collapses [55].
Recently, liquid chromatography-tandem mass spectrometry assay 
has been used for determining plasma level of MCF, administered in 
patients affected with IC. Assay timings were 20 minutes while the 
quantification was done at the lower limit of 0.1 mg/ml. This assay 
provides high specificity, accuracy and precision, can be a promising 
technique for quantification of plasma level of MCF [56].
However, a gel-free technique of isobaric tagging for relative and 
absolute quantitation [iTRAQ] is now accessible to get greater 
quantities of recognized proteins and to provide in-detail analysis. This 
technique practices a sequence of isobaric tags which links with lysines 
and the N terminal of every protein succeeding proteolysis [57,58]. 
Recently, the proteomic analysis of A. fumigatus against CAS has been 
estimated by iTRAQ technique to determine possible biomarkers of 
drug efficacy [59]. Using iTRAQ, out of 471 identified proteins 122 
proteins displayed at least a 2-fold difference in relative richness after 
exposure to CAS at just below the minimum effective concentration 
[0.12 g/ml] [60]. Lately, the major fluctuations have been observed in 
a protein [AFUA_1G12250] in mitochondria, whose intensity reduced 
more than 16 times in the secreted portion. Earlier studies revealed 
the probable importance of this protein as a biomarker exclusively to 
CAS as it was not reported while A. fumigatus was exposed to either 
voriconazole or AmpB [61-62].
Another is ChiA1, whose level declined 12.1 times in the cell 
wall/membrane portion. Previously, the protein encoded by Pma1 gene 
was reported to be raised 2 times against AmpB while reduced 4.3 times 
and 5.1 times after CAS exposure as determined by proteomics and 
microarray analysis [61]. The level of the key allergen and cytotoxin 
AspF1 has also been observed to drop by 12.1-fold after the supplement 
of the drug. A successive iTRAQ evaluation of an echinocandin-resistant 
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strain [fks1-S678P] was taken to authenticate proteins unambiguous to 
drug action. Also, Microarray analysis of non-resistant strain has been 
accomplished for assessment of the link that associates proteomics 
with genomics such that overall 117 genes were discovered which vary 
minimum by 2 times. However, 22 proteins with noteworthy deviations 
were acknowledged by iTRAQ also displayed substantial alterations in 
their level of gene expression analysed by microarray [61].
Recent studies used the combination of matrix-assisted laser desorption 
ionization-time of flight mass spectroscopy and two-dimensional 
polyacrylamide gel electrophoresis to recognize the modifications in 
protein richness in a strain of C. albicans following treatment with CAS. 
Mainly the proteins involved in glycolysis and gluconeogenesis gave 
response to CAS exposure, while other proteins reported to respond 
specifically to this drug found to be involved in cell stress and heat 
shock, and the proteins of the Kreb’s cycle and amino acid biosynthesis. 
Some enzymes catalyzing cell wall biosynthesis and the regulating BG 
synthase were also acknowledged [62].
FUTURE PROSPECTIVE
The medical practice with echinocandin drugs has been highly 
successful, as this class of drugs exhibit strong efficacy, especially 
with Candida spp., with negligible side effects and a low frequency of 
resistance. In future, its effect in combination with chelators can be 
explored. Moreover, it might give significant results with adjunctive 
immunotherapic agents under which research is under dogged. 
Echinocandins can be promising for novel drug design and might prove 
a milestone for the pharmaceutical industry in future.
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